Vontobel Holding Ltd. Reduces Position in ImmunityBio, Inc. $IBRX

Vontobel Holding Ltd. trimmed its holdings in shares of ImmunityBio, Inc. (NASDAQ:IBRX) by 37.5% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 10,000 shares of the company’s stock after selling 6,000 shares during the quarter. Vontobel Holding Ltd.’s holdings in ImmunityBio were worth $26,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Grimes & Company Inc. increased its position in shares of ImmunityBio by 484.4% during the second quarter. Grimes & Company Inc. now owns 58,436 shares of the company’s stock worth $154,000 after acquiring an additional 48,436 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of ImmunityBio by 39.6% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 34,095 shares of the company’s stock worth $90,000 after acquiring an additional 9,663 shares during the last quarter. Vigilare Wealth Management purchased a new stake in shares of ImmunityBio during the second quarter worth about $31,000. Wolff Wiese Magana LLC increased its position in shares of ImmunityBio by 5,900.0% during the second quarter. Wolff Wiese Magana LLC now owns 30,000 shares of the company’s stock worth $79,000 after acquiring an additional 29,500 shares during the last quarter. Finally, Plancorp LLC purchased a new stake in shares of ImmunityBio during the second quarter worth about $717,000. 8.58% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. D. Boral Capital reiterated a “buy” rating and issued a $24.00 price target on shares of ImmunityBio in a research note on Monday, September 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of ImmunityBio in a research note on Tuesday. Finally, HC Wainwright reiterated a “buy” rating and issued a $8.00 price target on shares of ImmunityBio in a research note on Wednesday, September 10th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, ImmunityBio currently has an average rating of “Moderate Buy” and an average target price of $10.75.

ImmunityBio Price Performance

NASDAQ:IBRX opened at $2.58 on Thursday. ImmunityBio, Inc. has a 12-month low of $1.83 and a 12-month high of $7.48. The firm has a market capitalization of $2.54 billion, a P/E ratio of -5.37 and a beta of 0.27. The business has a 50 day simple moving average of $2.50 and a 200 day simple moving average of $2.62.

ImmunityBio (NASDAQ:IBRX) last released its quarterly earnings data on Tuesday, August 5th. The company reported ($0.10) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.10). The company had revenue of $26.43 million for the quarter, compared to analyst estimates of $21.95 million. Research analysts anticipate that ImmunityBio, Inc. will post -0.92 EPS for the current fiscal year.

ImmunityBio Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.